News | February 20, 2012

Edwards Intuity Valve Receives CE Mark

February 20, 2012 — Edwards Lifesciences Corp. announced that it received CE mark in Europe for its Edwards Intuity valve system for use in patients undergoing surgical aortic valve replacement (AVR). The system, which consists of a bovine pericardial heart valve and novel delivery system, facilitates small incision surgery and rapid valve deployment during AVR procedures. The company plans to begin a disciplined European launch at centers participating in post-approval clinical studies.

"Minimally invasive therapies are increasingly being sought by patients because of their demonstrated benefits, and the Edwards Intuity valve system allows us to provide small incision aortic valve replacement with a proven valve platform," said professor Michael Borger, M.D., Ph.D., associate director of the department of cardiac surgery at the Leipzig Heart Center in Germany and investigator in the TRITON study, which evaluated the feasibility, safety and performance of the Edwards Intuity valve system. "This system includes unique features designed to facilitate a faster and more efficient procedure, so physicians have the opportunity to provide patients a desired therapeutic option without added procedural complexity."

The Edwards Intuity valve system leverages the design of Edwards' pericardial valve technology, which is based on the company's nearly 30-year leadership in tissue valve design. The valve features an innovative balloon-expandable frame designed to facilitate rapid and secure annular placement intended to reduce overall procedural time. The novel delivery system is designed to enable control, accuracy and simplicity throughout implantation.

"This system was developed with key insights and learnings from leading surgeons, and demonstrates our commitment to continued innovation in surgical heart valve therapy," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "We are excited about the promise of this technology to advance the current standard of care for clinicians and their patients."

The Edwards Intuity valve system is not yet available for sale or use in the United States.

For more information:

Related Content

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init